The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address medical needs. Co.'s product candidates include: PTG-100, which has potential as an oral, alpha-4-beta-7 integrin-specific antagonist for the treatment of inflammatory bowel disease (IBD); PTG-200, which is Co.'s second oral, gastrointestinal-restricted peptide product candidate and a potential Interleukin-23 receptor specific antagonist for the treatment of IBD; and PTG-300, which is an injectable hepcidin mimetic peptide that Co. is developing for the treatment of iron overload disorders.

PTGX SEC Filing Email Alerts Service

Company Name:  Protagonist Therapeutics Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PTGX:  8
Total Market Value Held by ETFs:  $5.73M
Total Market Capitalization:  $372.00M
% of Market Cap. Held by ETFs:  1.54%
December 17, 2017    12:21 PM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Protagonist Therapeutics Inc (PTGX) Page | The Online Investor | | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.